Tuberculosis and HIV—progress towards the 2020 target. Geneva: Joint United Nations Programme on HIV/AIDS; 2019. https://www.unaids.org/en/resources/documents/2019/tuberculosis-and-hiv-progress-towards-the-2020-target. Accessed 20 Oct 2021.
Global tuberculosis report 2022. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.
Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29:1987–2002.
Tuberculosis Surveillance Center. Tuberculosis in Japan—annual report 2022. Tokyo: Research Institute of Tuberculosis; 2022. https://jata-ekigaku.jp/english/tb-in-japan. Accessed 1 Nov 2022.
AIDS surveillance committee. Annual AIDS Report 2021. Tokyo: Ministry of Health, Labour and Welfare; 2022. https://api-net.jfap.or.jp/status/japan/nenpo.html. Accessed 25 Oct 2021.
Iwamoto A, Taira R, Yokomaku Y, Koibuchi T, Rahman M, Izumi Y, Tadokoro K. The HIV care cascade: Japanese perspectives. PLoS ONE. 2017;12(3):e0174360.
Article PubMed PubMed Central Google Scholar
A list of designated HIV/AIDS hospitals. https://hiv-hospital.jp/. Accessed 1 Nov 2022.
A list of certified HIV/AIDS physicians. https://jaids.jp/qualification/list_d/. Accessed 1 Nov 2022. (in Japanese).
Kawatsu L, Uchimura K, Kaneko N, Imahashi M. Epidemiology of tuberculosis and HIV/AIDS co-infection in Japan. Western Pac Surveill Response J. 2022;13(1):1–8.
PubMed PubMed Central Google Scholar
HIV kansenshou – chiryou no tebiki. Dai 25 han. (Treatment guideline on HIV infection. 25th edition). November 2021. Research Group for Therapy of HIV Infection. http://www.hivjp.org/guidebook/. Accessed 25 Oct 2021.
Ko-HIV chiryou-guideline (Guideline on combined anti-retro virus therapy). March 2022. https://hiv-guidelines.jp/index.htm. Accessed 1 Apr 2022.
HIV kansensho shindan, chiryoum kango manual (Manual on diagnosis, treatment and care for HIV positive patients). Hokkaido University. Updated March 2021. https://www.hok-hiv.com/for-medic/download/manual.html. Accessed 1 Apr 2022.
EACS Guidelines 2022. Version 11.1. European AIDS Clinical Society. https://eacs.sanfordguide.com/. Accessed 25 Oct 2022.
Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Disease Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new. Accessed 1 Oct 2022.
British HIV Association. British HIV Association guidelines for management of tuberculosis in adults living with HIV 2018 (2022 interim updates). https://www.bhiva.org/TB-guidelines. Accessed 1 Apr 2022.
Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard G, Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma JK. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391.
Article PubMed PubMed Central Google Scholar
World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update 2019. Geneva: World Health Organization; 2019.
Towards tuberculosis elimination: an action framework for low-incidence countries. Geneva: WHO; 2014. License: CC BY-NC-SA 3.0 IGO
De Vries G, van der Berg S, van Dam A, Hasanoba S, Pareek M, van der Werf M, Podlekareva DN. Collaborative tuberculosis/HIV activities in the European region. ERJ Open. 2021;7:00721–2020.
WHO consolidated guidelines on tuberculosis. Module 1: prevention—tuberculosis preventive treatment. License: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2020.
WHO consolidated guidelines on tuberculosis. Module 2: screening—systematic screening for tuberculosis disease. License: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2021.
Cattamanchi A, Smith R, Steingart K, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell P, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–8.
Article PubMed PubMed Central CAS Google Scholar
Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis. 2006;43(5):634–9.
Sester M, van Leth F, Brunchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168–76.
Gutsfeld C, Olaru IO, Vollrath O, Lange C. Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PLoS ONE. 2014;9:e112681.
Article PubMed PubMed Central Google Scholar
Brassard P, Hottes TS, Lalonde RG, Klein MB. Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. Can J Infect Dis Med Microbiol. 2009;20:51–7.
Article PubMed PubMed Central Google Scholar
Norbeck E, Lock M, editors. Health, illness, and medical care in Japan. Honolulu: University of Hawaii Press; 1987.
Iwata K, Doi A, Higasa S. Current status and future prospects of AIDS core hospitals in Japan. J AIDS Res. 2018;20:179–85 (in Japanese).
Nakagawa Y, Moro H, Kawagushi S, Uchiyama M, Shinbo A, Saigusa Y, Noda J, Suzuki H, Shibata S, Cho H, Sato M, Kikuchi T. Medical workers anxiety about accepting HIV infected persons—examination from HIV external workshop questionnaire. J AIDS Res. 2021;23:113–21 (in Japanese).
Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS ONE. 2021;7(3):e32482.
Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(suppl_4):S1120–9.
Article PubMed PubMed Central Google Scholar
Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among US-born people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2021;73(7):e2278–84.
Article PubMed CAS Google Scholar
Fukushima K, Kubo T, Akagi K, Takazono T, Sakamoto N, Mukae H. Clinical evaluation of QuantiFERON®-TB Gold Plus directly compared with QuantiFERON®-TB Gold In-Tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly. J Infect Chemother. 2021;27(12):1716–22.
Article PubMed CAS Google Scholar
Igari H, Ishikawa S, Nakazawa T, Oya Y, Futami H, Tsuyuzaki M, Suzuki K, Matsumura R. Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis. J Infect Chemother. 2018;24:110–6.
Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401–9.
Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes GM, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283(11):1445–50.
Article PubMed CAS Google Scholar
Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292–7.
Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689–97.
Evenblij K, Verbon A, van Leth F. Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design. BMC Public Health. 2016;16(1):915. https://doi.org/10.1186/s12889-016-3539-2.
Article PubMed PubMed Central Google Scholar
Wyndham-Thomas C, Schepers K, Dirix V, Mascart F, Van Vooren JP, Goffard JC. Implementation of latent tuberculosis screening in HIV care centers: evaluation in a low tuberculosis incidence setting. Epidemiol Infect. 2016;144:703–11.
Article PubMed CAS Google Scholar
Fox-Lewis A, Brima N, Muniina P, Grant AD, Edwards SG, Miller RF, Pett SL. Tuberculosis screening in patients with HIV: an audit against UK national guidelines to assess current practice and the effectiveness of electronic tuberculosis screening prompt. Int J STD AIDS. 2016;27:901–5.
Article PubMed CAS Google Scholar
Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: a multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. Int J Infect Dis. 2020;92:62–8.
Reaves EJ, Shah NS, France AM, Morris SB, Kammerer S, Skarbinski J, Bradley H. Latent tuberculosis infection testing among HIV-infected persons in clinical care, United States, 2010–2012. Int J Tuberc Lung Dis. 2017;21:1118–26.
Article PubMed CAS Google Scholar
Sugai M, Yoshimochi M, Centenotamura K, Suzuki T, Tsuji N, Iuchi A, Hamamoto K, Tanabe Y, Ito T. Current status of AIDS Core Hospital: from AIDS Core Hospital List. J AIDS Res. 2015;17(3):184–6 (in Japanese).
留言 (0)